Rainer K. Brachmann

2.8k total citations
40 papers, 2.3k citations indexed

About

Rainer K. Brachmann is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rainer K. Brachmann has authored 40 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 26 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rainer K. Brachmann's work include Cancer-related Molecular Pathways (11 papers), Ubiquitin and proteasome pathways (6 papers) and Epigenetics and DNA Methylation (5 papers). Rainer K. Brachmann is often cited by papers focused on Cancer-related Molecular Pathways (11 papers), Ubiquitin and proteasome pathways (6 papers) and Epigenetics and DNA Methylation (5 papers). Rainer K. Brachmann collaborates with scholars based in United States, China and Japan. Rainer K. Brachmann's co-authors include Ting Wang, Jue Zeng, Rik Derynck, Mariko Nagashima, Terry Lipari, William J. Kohr, Mary A. Napier, Patricia B. Lindquist, Jef D. Boeke and Qian Hua and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Rainer K. Brachmann

40 papers receiving 2.2k citations

Peers

Countries citing papers authored by Rainer K. Brachmann

Since Specialization

Citations

This map shows the geographic impact of Rainer K. Brachmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainer K. Brachmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainer K. Brachmann more than expected).

Fields of papers citing papers by Rainer K. Brachmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainer K. Brachmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainer K. Brachmann. The network helps show where Rainer K. Brachmann may publish in the future.

Co-authorship network of co-authors of Rainer K. Brachmann

This figure shows the co-authorship network connecting the top 25 collaborators of Rainer K. Brachmann. A scholar is included among the top collaborators of Rainer K. Brachmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rainer K. Brachmann. Rainer K. Brachmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer 2020 ·Clinical Cancer Research ·Efrat Dotan, Dana B. Cardin, Heinz‐Josef Lenz, Wells A. Messersmith, Bert H. O’Neil, Steven J. Cohen, Crystal S. Denlinger, Safi Shahda, Igor Astsaturov, Ann M. Kapoun, Rainer K. Brachmann, Shailaja Uttamsingh, Robert Stagg, Colin D. Weekes	59
2	Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer 2020 ·Breast Cancer Research and Treatment ·Jennifer R. Diamond, Carlos Becerra, Donald Richards, Alain C. Mita, Cynthia R. Osborne, Joyce O’Shaughnessy, Chun Zhang, (unknown), Ann M. Kapoun, Lu Xu, (unknown), Shailaja Uttamsingh, Rainer K. Brachmann, Azeez Farooki, Monica Mita	103
3	A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer 2019 ·Gynecologic Oncology ·Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone, Robert A. Burger, Mark A. Morgan, Ann M. Kapoun, Rainer K. Brachmann, Robert Stagg, Azeez Farooki, Roisin E. O’Cearbhaill	79
4	A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors 2014 ·Investigational New Drugs ·Colin D. Weekes, Muralidhar Beeram, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Lia Gore, Priti S. Hegde, Xin Yan, Ron Yu, L-Y Shih, Hong Xiang, Rainer K. Brachmann, Amita Patnaik	72
5	A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Patricia LoRusso, Wells A. Messersmith, Kyriakos P. Papadopoulos, Lia Gore, Muralidhar Beeram, Vanitha Ramakrishnan, (unknown), Joseph C. Beyer, L-Y Shih, Walter C. Darbonne, Xin Yan, Ron Yu, Hong Xiang, Rainer K. Brachmann, Colin D. Weekes	61
6	Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors. 2013 ·Molecular Cancer Therapeutics ·David C. Smith, Michael S. Gordon, Wells A. Messersmith, Rashmi Chugh, David S. Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Rainer K. Brachmann, Antonio Jimeno	16
7	Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Xin Yan, Jessica Li, Jenny Wu, (unknown), Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer K. Brachmann, Raymond K. Tong, Yibing Yan, Ryan J. Watts, Shuang Bai, Priti S. Hegde	33
8	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models 2012 ·Clinical Cancer Research ·Jill M. Spoerke, Carol O’Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, Mark R. Lackner	149
9	Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans 2012 ·Pharmaceutical Research ·Xin Yan, Shuang Bai, Lisa A. Damico‐Beyer, (unknown), Wei‐Ching Liang, Yan Wu, Frank‐Peter Theil, Amita Joshi, Yanmei Lu, John Lowe, Mauricio Maia, Rainer K. Brachmann, Hong Xiang	25
10	p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5 2010 ·International Journal of Cancer ·Takahiko Kobayashi, (unknown), Manabu Musashi, Shuichi Ota, Takeshi Yoshida, Yuichi Shimizu, Makoto Chuma, (unknown), Masahiro Asaka, Junji Tanaka, Masahiro Imamura, Masanobu Kobayashi, Hiroshi Itoh, Hironori Edamatsu, Leslie C. Sutherland, Rainer K. Brachmann	24
11	Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteins 2007 ·Nucleic Acids Research ·Jue Zeng, Jizhou Yan, Ting Wang, Deborah Mosbrook-Davis, Kyle Dolan, Ryan Christensen, Gary D. Stormo, David Haussler, Richard H. Lathrop, Rainer K. Brachmann, Shawn M. Burgess	21
12	Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers 2006 ·Carcinogenesis ·(unknown), Qian Hua, Ting Wang, Timothy E. Baroni, Jue Zeng, (unknown), Sun Young Yi, Rainer K. Brachmann	105
13	Overexpression of the Oncoprotein Prothymosin α Triggers a p53 Response that Involves p53 Acetylation 2006 ·Cancer Research ·Takahiko Kobayashi, Ting Wang, (unknown), Masanobu Kobayashi, Shunsuke Ohnishi, Kazuteru Hatanaka, Shuhei Hige, Yuichi Shimizu, (unknown), Masahiro Asaka, Junji Tanaka, Masahiro Imamura, Kiminori Hasegawa, Yoshiyuki Tanaka, Rainer K. Brachmann	27
14	p53 interacts with the spliceosomal protein SAP145 and affects pre-mRNA processing 2005 ·Cancer Research ·Lan N. Truong, Klemens J. Hertel, Rainer K. Brachmann	3
15	Genetic Strategies in Saccharomyces cerevisiae to Study Human Tumor Suppressor Genes 2003 ·Humana Press eBooks ·Takahiko Kobayashi, Ting Wang, Qian Hua, Rainer K. Brachmann	6
16	Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites 2002 ·Oncogene ·Qian Hua, Ting Wang, Louie Naumovski, Charles D. Lopez, Rainer K. Brachmann	109
17	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations 1998 ·The EMBO Journal ·Rainer K. Brachmann, Kexin Yu, Yolanda Eby, Nikola P. Pavletich, Jef D. Boeke	141
18	Recombinant expression, biochemical characterization and biological activities of the human MGSA/gro protein 1990 ·Biochemistry ·Erik De Clercq, Jin Hee Han, (unknown), Duanzhi Wen, (unknown), Claus Zachariae, Patrick R. Griffin, Rainer K. Brachmann, (unknown)	114
19	Expression of c‐sis and other cellular proto‐oncogenes in human sarcoma cell lines and biopsies 1989 ·International Journal of Cancer ·(unknown), Rainer K. Brachmann, K. von der Helm	12
20	Transmembrane TGF-α precursors activate EGF/TGF-α receptors 1989 ·Cell ·Rainer K. Brachmann, Patricia B. Lindquist, Mariko Nagashima, William J. Kohr, Terry Lipari, Mary A. Napier, Rik Derynck	364

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact